User:Coteswayed/sandbox

Liona Chiu Yee Poon
Born
Leona Chiu Yee Poon

Hong Kong
Known forPrediction and prevention of preeclampsia. Prenatal diagnosis. High-risk obstetrics. Maternal Fetal Medicine.
Academic background
Alma materUniversity of London, The Chinese University of Hong Kong
Academic work
InstitutionsChinese University of Hong Kong
King's College London

Liona Poon is an obstetrician-gynaecologist with clinical research interests devoted to improving women’s and children’s health. Poon is currently the Chairperson of the Department of Obstetrics and Gynaecology at the Chinese University of Hong Kong and a visiting Professor at the Department of Women and Children’s Health, King's College London.[1]

Biography

edit

Poon completed primary school (Holy Family Canossian School, St Frances of Assisi's Caritas School) and proceeded to secondary school at St Mary's Canossian College in 1991. At the age of 14, Poon decided firmly that she would pursue a career as a clinical doctor, and in the same year, she left Hong Kong to study in the UK. She attended Abbots Bromley School for Girls, Staffordshire, UK, for GSCS and A levels. She received her Bachelor of Medicine and Surgery, MBBS[2] degree at Guy’s King’s and St Thomas’ School of Medicine, University of London, in 2002, with distinction in Special Study Modules.

Her first involvement in research was on Nicolaides’ progesterone trial for the prevention of preterm birth, and soon after that she began her own postgraduate project on first trimester prediction of preeclampsia. In 2011, one year after obtaining her MRCOG (Royal College of Obstetricians and Gynaecologists), Poon graduated with a MD(Res)[2] degree, also at Guy’s King’s and St Thomas’ School of Medicine, under the supervision of Nicolaides.

In the last 20 years she has focused her research on establishing a programme for effective early prediction and prevention of preeclampsia.[3]

Poon was the first researcher to have developed an effective first trimester prediction model based on a combination of maternal factors, blood pressure, uterine artery Doppler, serum pregnancy-associated plasma protein-A and placental growth factor for early-onset preeclampsia, achieving a detection rate of 90%, at 5% false-positive rate. Working together with the Fetal Medicine Foundation team, the first trimester prediction model has evolved from a multivariate logistic regression model to a novel Bayes theorem-based model that incorporates a survival-time model for the gestational age at delivery with preeclampsia.[4] The benefit of using the Bayes theorem-based method is that when future research identifies new effective biomarkers, they can easily be incorporated within the Bayes paradigm.[4]

In addition, Poon’s work in the area of preeclampsia led to a double-blinded randomised controlled trial of low-dose aspirin in pregnancies identified as high-risk of preeclampsia following first-trimester screening (ASPRE trial).[5] This study was awarded a major grant from the European Union 7th Framework Programme with Poon as the Co-Chief Investigator of the project.[6] The trial demonstrated that the use of low-dose aspirin from 11 to 14 weeks’ gestation reduced the rate of preterm preeclampsia with delivery before 37 weeks’ gestation by 62%.[7] This work has been published in the New England Journal of Medicine and has gained tremendous attention internationally. The ASPRE trial is a landmark study illustrating the possibility of effective first-trimester screening and prevention of pregnancy complications.

Poon relocated back to Hong Kong in 2016 and was appointed by The Chinese University of Hong Kong (CUHK) as an Associate Professor at the Department of Obstetrics and Gynaecology in 2016. In 2018, Poon was promoted to Professor (Clinical).[8] In January 2022, Poon was appointed Chairperson of the Department of Obstetrics and Gynaecology, Chinese University of Hong Kong.[9] In the same year, she obtained FHKCOG, FHKAM (Obstetrics and Gynaecology).

Research Interest

edit

1st trimester screening; fetal biometry and wellbeing; fetal anomalies screening; aneuploidy screening; fetal anomalies; fetal growth restriction; maternal and fetal Doppler; maternal haemodynamics; multiple pregnancy; preeclampsia; preterm delivery; fetal growth; detection of fetal growth abnormalities; fetal neurosonography; ultrasound on labor ward.

Selected publications

edit
  • Li X, Milosavljevic A, Elsea SH, Wang CC, Scaglia F, Syngelaki A, Nicolaides KH, Poon LC. Effective Aspirin Treatment of Women at Risk for Preeclampsia Delays the Metabolic Clock of Gestation. Hypertension 2021; 78:1398-1410.
  • Chaemsaithong P, Pooh RK, Zheng M, Ma R, Chaiyasit N, Tokunaka M, Shaw SW, Seshadri S, Choolani M, Wataganara T, Yeo GSH, Wright A, Leung WC, Sekizawa A, Hu Y, Naruse K, Saito S, Sahota D, Leung TY, Poon LC. Prospective evaluation of screening performance of first trimester prediction models for preterm preeclampsia in Asian population. Am J Obstet Gynecol. 2019 Dec;221(6):650.e1-650.e16.  doi: 10.1016/j.ajog.2019.09.041.
  • Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R, Singh M, Andrade W, Efeturk T, Jani JC, Plasencia W, Papaioannou G, Blazquez AR, Carbone IF, Wright D, Nicolaides KH. ASPRE trial: incidence of preterm preeclampsia in patients fulfilling ACOG and NICE criteria according to risk by the FMF algorithm. Ultrasound Obstet Gynecol. 2018 Jun;51(6):738-742.
  • Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, Leipold G, Akolekar R, Shearing S, De Stefani L, Jani JC, Plasencia W, Evangelinakis N, Gonzalez-Vanegas O, Persico N, Nicolaides KH. ASPRE trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history.  Am J Obstet Gynecol. 2017 Nov;217(5):585.e1-585.e5.  doi: 10.1016/j.ajog.2017.07.038. Epub 2017 Aug 4.
  • Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tennebaum Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus Placebo in Pregnancies at High Risk of Preterm Preeclampsia. N Engl J Med. 2017 Aug 17;377(7):613-622. doi: 10.1056/NEJMoa1704559. Epub 2017 Jun 28.
  • Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812-818.

References

edit
  1. ^ "Liona Poon - Research Portal, King's College, London". KCL.
  2. ^ a b "Liona Poon". King's College London.
  3. ^ Keener, Amanda (17 April 2020). "Pre-eclampsia Symptoms, Treatment and Prevention". The New York Times.
  4. ^ a b "CUHK Validates the Enhanced UK Fetal Medicine Foundation's Triple Test Can Double the Detection Rate of Preterm Preeclampsia in Asian Pregnant women". Asia Research News.
  5. ^ "CUHK Validates the Enhanced UK Fetal Medicine Foundation's Triple Test Can Double the Detection Rate of Preterm Preeclampsia in Asian Pregnant women". Asia Research News.
  6. ^ "Final Report Summary - ASPRE (Combined Multi-marker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Pre-eclampsia Prevention) | FP7". CORDIS | European Commission.
  7. ^ "Aspirin reduces risk of pre-eclampsia in pregnant women". ITV News.
  8. ^ "Prof. Poon Chiu Yee, Liona – O&G CUHK". The Chinese University of Hong Kong.
  9. ^ "Professor POON Chiu Yee, Liona - Chairpersons of Departments - Faculty Management - People - About Us - Faculty of Medicine". Chinese University of Hong Kong.
edit